1. Scrip
  2. >>Business
  3. >>Strategy

CytoDyn In Damage-Control Mode (Again) With Clinical Holds For Leronlimab

 
• By Joseph Haas

Troubled leronlimab is placed on partial clinical hold in HIV, full clinical hold in COVID-19. While searching for a new CEO, CytoDyn tries to reassure investors about its business plan going forward.

Cease and desist
A pair of FDA clinical holds create further questions around leronlimab • Source: Alamy

Turbulence continues at CytoDyn, Inc. as executives at the company, which dismissed its CEO amidst controversy in January, tried to assure investors on 31 March about the business plan moving forward despite the US Food and Drug Administration putting two clinical holds for its lead candidate leronlimab, in both HIV and COVID-19.

Following the stock market closing on 30 March, CytoDyn announced that the FDA had placed a partial clinical hold on leronlimab, a CCR5-binding antibody, in HIV and a full clinical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business